0001140361-21-035751.txt : 20211028 0001140361-21-035751.hdr.sgml : 20211028 20211028161405 ACCESSION NUMBER: 0001140361-21-035751 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211027 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211028 DATE AS OF CHANGE: 20211028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kinnate Biopharma Inc. CENTRAL INDEX KEY: 0001797768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824566526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39743 FILM NUMBER: 211358384 BUSINESS ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8582994699 MAIL ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 brhc10030201_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2021



KINNATE BIOPHARMA INC.
(Exact name of Registrant as Specified in Its Charter)



Delaware
001-39743
82-4566526
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
3611 Valley Centre Drive, Suite 175
   
San Diego, California
 
92130
(Address of Principal Executive Offices)
 
(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 299-4699

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading
Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
 
KNTE
 
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

Effective as of December 3, 2021, Eric Murphy, Ph.D. will cease serving as the Chief Scientific Officer of Kinnate Biopharma Inc. (the “Company”) and begin serving as a member of the Company’s Scientific Advisory Board (the “SAB”).  Dr. Murphy will be paid an hourly fee for his service on the SAB based on his experience and qualifications commensurate with the fees paid to other members of the SAB.

Item 8.01
Other Events

On October 28, 2021, the Company issued a press release announcing the transition of Dr. Murphy from Chief Scientific Officer of the Company to member of the SAB.  The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
Description
Press Release dated October 28, 2021


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
KINNATE BIOPHARMA INC.
     
 
By: 
/s/ Nima Farzan  
Date:  October 28, 2021

Nima Farzan
 
 

Chief Executive Officer and President
 



EX-99.1 2 brhc10030201_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1


Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer

Dr. Eric Murphy to serve on the company’s Scientific Advisory Board

SAN FRANCISCO and SAN DIEGO, Calif. – October 28, 2021 – Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the company’s Chief Scientific Officer, Eric Murphy, Ph.D., will step down from that role on December 3, 2021 to pursue a new opportunity.  Dr. Murphy will remain an important scientific adviser to Kinnate and will continue to support the company by serving on its Scientific Advisory Board.

“On behalf of the Kinnate team, we are incredibly grateful to Eric for his contributions to the company as its co-founder and wish him all the best as he pursues his next entrepreneurial endeavor,” said Nima Farzan, Chief Executive Officer of Kinnate. “Kinnate is in an exciting time of growth built on the incredible contributions of our talented team who this year have powered our successful IND for KIN-2787 and the initiation of our Phase 1 clinical trial, presented data from our expanding pipeline at major medical meetings and managed our expansion into China.”

Kinnate was founded in 2018 to develop small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Since then, Kinnate has established a pipeline of multiple assets, including KIN-2787 which is currently in a Phase 1 trial for adult patients with BRAF mutant advanced and metastatic solid tumors, and KIN-3248 for which an Investigational New Drug application (IND) is anticipated in the first half of 2022. Leveraging the company’s discovery engine, Kinnate is also pursuing a number of other small molecule development programs.

“It has been a privilege to work with such a dedicated team to build a targeted therapy pipeline focused on specific patient needs.  I am extremely proud of the team’s accomplishments to date and excited to see what they do in the future,” said Dr. Murphy. “I am honored to join the esteemed members of Kinnate’s Scientific Advisory Board and look forward to remaining involved in the company’s success.”

About Kinnate
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.

Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, without limitation, statements regarding our discovery and research activities and pipeline, the potential benefits of our product candidates, the expected timing of our regulatory filings and the conduct of our clinical trials. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors, including risks related to operating as a preclinical-stage biopharmaceutical company with a limited operating history; our ability to raise additional capital to finance our operations; our ability to discover, advance through the preclinical and clinical development of, obtain regulatory approval for and commercialize our product candidates; the novel approach we are taking to discover and develop drugs; our ability to timely file and obtain approval of investigational new drug applications for our planned clinical trials; the potential for any clinical trial results to differ from our preclinical trial results; negative impacts of the COVID-19 pandemic on our business, including ongoing and planned clinical trials and ongoing and planned preclinical trials; competition in our industry; regulatory developments in the United States and other countries; our ability to attract, hire and retain highly skilled executive officers and employees; difficulties in managing our growth; our ability to protect our intellectual property; reliance on third parties to conduct our preclinical studies and ongoing and planned future clinical trials, and to manufacture our product candidates; general economic and market conditions; and other risks.

These and other risks, uncertainties, assumptions and other factors are further described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.


Contacts:

Investors:
Patti Bank
Westwicke, an ICR Company
415-513-1284
investors@kinnate.com

Media:
Colin Sanford
colin@bioscribe.com



EX-101.SCH 3 knte-20211027.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 knte-20211027_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 knte-20211027_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00006.jpg begin 644 image00006.jpg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brhc10030201_8k_htm.xml IDEA: XBRL DOCUMENT 0001797768 2021-10-27 2021-10-27 false 0001797768 8-K 2021-10-27 KINNATE BIOPHARMA INC. DE 001-39743 82-4566526 3611 Valley Centre Drive Suite 175 San Diego CA 92130 858 299-4699 false false false false Common Stock, $0.0001 par value per share KNTE NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 27, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 27, 2021
Entity Registrant Name KINNATE BIOPHARMA INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39743
Entity Tax Identification Number 82-4566526
Entity Address, Address Line One 3611 Valley Centre Drive
Entity Address, Address Line Two Suite 175
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 299-4699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001797768
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol KNTE
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,&!7%,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #!@5Q3:X5O:.\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:9%T=#E9<,G!<&!XEM(;EM8TX3DI-VWMXU;A^@'\#%W__SN M=W"M#D+[B"_1!XQD,=V,KNN3T&'%#D1! "1]0*=2.27ZJ;GST2F:GG$/0>FC MVB/4574'#DD910IF8!$6(I.MT4)'5.3C&6_T@@^?L M&$YCU\(5,,,(HTO?!30+,5?_Q.8.L'-R3'9)#<-0#DW.33MP>']^>LWK%K9/ MI'J-TZ]D!9T"KMAE\ENSWFP?F:RKFA>\*NK[;5T)WHC;AX_9]8??5=AY8W?V M'QM?!&4+O^Y"?@%02P,$% @ P8%<4YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #!@5Q3UU]A?',$ "+$0 & 'AL+W=O_0L/THIU)8EM\[Q!F'$BZ3#:$!KH[TTXOA"U $]MR)3F$ M?]\C S:[:XYI;[!E^[Q^=([\2F*PE>I5;S@WY#V.$GW;V!B3?G0<'6QXS/2- M3'D"=U92Q:*%3(CBJ]N&[WV\ MHQT;D#_Q1?"M/CDGMBM+*5]M8Q+>-EQ+Q",>&"O!X/#&1SR*K!)P_',0;13O MM(&GYT?UA[SST)DETWPDHZ\B-)O;1J]!0KYB661>Y/83/W2H;?4"&>G\EVSW MS[9:#1)DVLCX$ P$L4CV1_9^2,1I #T30 \!-.?>ORBG'#/#A@,EMT39IT'- MGN1=S:,!3B2V*G.CX*Z .#,LTS>B/YQA7YRU]JHZ"$?R.2 MS4*RF4NVZOJ\V*6\JH=X>._Z$8%H%1 M5,4'@C"G>(C8NHH"CU^Q2'.$HUUP MM"]+QHPK(>T8" F,I,J\X$K'RO_TX4--[3L%6P=5/(S'%[X6MOH .65Q)1FN M\SB93OW%/;F;/,\^^2]//IE,1S<(8+< [%X".$D"J5*I\D_FBLP-Y(](148R M2XS:P3&LI,;%Q_<(8:\@[%U"^" B3J99O.2J"@37<%WONMGOMIH(3[_@Z5_" MLV#O9!+"L!,K$>1I0^APQ1Z];K4[G3;M('B>6_JA>PF@'X:*:WUU/"&?X3GR MG%36L4:RV?$\\H5%$8>A 'U6G(P5S$48[XE_>_^?=[&5E;RXY#P3,'Z];AL# M+/W;H_\)<&1;\'$LY+9Z>L'EYBPA8\'7$H,K9P(/]_+OX8I/=Z;DFTB"ZG+C MFB,?0ROG!P\W^._19E(;%I$_17K63VH4^]1KNAA;.6=XN-7G-?1A%7@>!1?H MM7L82#E!>+BS?Y8!Y&2VD0EF;S4BM-^_;G7Z?8RHG!$\W+6_*F$,3R Q<9PE M!W/3E52X4-T$[Y53@(?[]UQ&(A!&)&OR!,-;"195\N JM3SE%.#ACCU3_#J M]'#XOO;K,%@*P2+O>;4Z4S]OY&RB8C1UL*4MVE6BXH%$92G:R3+_(YN_?R0)6:EKD<_I^35F)A:O5 M9JQT>'J1P^?S+EC%! KY3AYY=:YP*1<60MU^M]O!O(N6!D]Q.UX( XLRN2(> M_67Y*YGS( /OJ ;#E:S70+;G1@:O5^1G]\:2DI0I\L:BC),4QJ[>,(5FM#1_ MBGLWU#>T8V^^BY>RTDEJ!!ZG"VQI2TOWI[AQ'U,&HR[8L&3-S^X/:H2F_GSL M_U[%Y)QLK>W?%$_,?GB:1'P%2NY-%[JJ]CO_?&PO9KEMWDOSAR+DCO9*ZW="C<\W[ M)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3 M;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@ M:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_& M%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V M_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUS MS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D M^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>P MSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0 M_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^& M<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8 M[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( ,&!7%.7BKL< MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+ MD6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+ M)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\ M@2P/73>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0 M ( ,&!7%,D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&R MGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0 MDBBZ0=@S9)[NF:*'3^ 5!+ M P04 " #!@5Q399!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX M;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85- MK'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+ MY8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE# MVQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/) MW55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_ ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( ,&!7%,'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ P8%< M4VN%;VCO *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ P8%<4YE&PO=V]R:W-H965T&UL4$L! A0#% @ P8%<4Y^@&_"Q @ X@P T ( ! MMPP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L! A0#% @ P8%<4R0>FZ*M ^ $ !H ( !Z!$ M 'AL+U]R96QS+W=O9(9 0 SP, !, ( !S1( %M#;VYT96YT7U1Y<&5S72YX 8;6Q02P4& D "0 ^ @ %Q0 end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://kinnate.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10030201_8k.htm brhc10030201_ex99-1.htm knte-20211027.xsd knte-20211027_lab.xml knte-20211027_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10030201_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10030201_8k.htm" ] }, "labelLink": { "local": [ "knte-20211027_lab.xml" ] }, "presentationLink": { "local": [ "knte-20211027_pre.xml" ] }, "schema": { "local": [ "knte-20211027.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "knte", "nsuri": "http://kinnate.com/20211027", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10030201_8k.htm", "contextRef": "c20211027to20211027", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://kinnate.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10030201_8k.htm", "contextRef": "c20211027to20211027", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001140361-21-035751-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-035751-xbrl.zip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end